Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

Aqueous Humor Proteome Analysis in Conbercept-treated Retinal Vein Occlusion With Macular Edema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07106268

Enrollment

100

Registered

2025-08-06

Start date

2023-03-01

Completion date

2025-09-30

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Vein Occlusion

Brief summary

the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is: What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage * Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened * Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm * Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery * The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram

Exclusion criteria

* Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation * Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases * Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Design outcomes

Primary

Measure	Time frame	Description
Central retinal thickness	March 2023 - June 2024	The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients

Secondary

Measure	Time frame	Description
Best corrected visual acuity	March 2023 - June 2024	BCVA was measured using logarithm of the minimum angle of resolution (LogMAR) chart

Countries

China

Outcome results